 Merrimack Pharmaceuticals Inc. said its treatment for advanced pancreatic cancer helped extend patients' lives by nearly two months compared with a control group in a late-stage study, a statistically significant survival advantage in a condition where some patients live just a few months after diagnosis with advanced disease. . Merrimack, based in Cambridge, Mass., said it would seek regulatory approval for the drug, called MM-398, as a second-line treatment later this year. It announced the results in a statement, and said...
  